NCT03088540 2026-02-23Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Regeneron PharmaceuticalsPhase 3 Completed712 enrolled 2 FDA
NCT02486718 2026-02-05Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]Hoffmann-La RochePhase 3 Active not recruiting1,280 enrolled 24 charts 2 FDA
NCT03456076 2026-01-30A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerHoffmann-La RochePhase 3 Active not recruiting257 enrolled 14 charts 2 FDA
NCT02477826 2025-10-30CheckMate 227Bristol-Myers SquibbPhase 3 Completed2,747 enrolled 21 charts 3 FDA
NCT03425643 2024-12-03MK-3475-671Merck Sharp & Dohme LLCPhase 3 Active not recruiting797 enrolled 23 charts 2 FDA
NCT02409342 2023-03-15A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]Hoffmann-La RochePhase 3 Completed572 enrolled 32 charts 3 FDA